This company has been marked as potentially delisted and may not be actively trading. Sinovac Biotech (SVA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsDividendFDA EventsHeadlinesOptions ChainOwnershipTrendsBuy This Stock SVA vs. MLYS, TARS, CDTX, ALVO, FOLD, BEAM, IDYA, BLTE, IRON, and IBRXShould you be buying Sinovac Biotech stock or one of its competitors? The main competitors of Sinovac Biotech include Mineralys Therapeutics (MLYS), Tarsus Pharmaceuticals (TARS), Cidara Therapeutics (CDTX), Alvotech (ALVO), Amicus Therapeutics (FOLD), Beam Therapeutics (BEAM), IDEAYA Biosciences (IDYA), Belite Bio (BLTE), Disc Medicine (IRON), and ImmunityBio (IBRX). These companies are all part of the "med - biomed/gene" industry. Sinovac Biotech vs. Its Competitors Mineralys Therapeutics Tarsus Pharmaceuticals Cidara Therapeutics Alvotech Amicus Therapeutics Beam Therapeutics IDEAYA Biosciences Belite Bio Disc Medicine ImmunityBio Sinovac Biotech (NASDAQ:SVA) and Mineralys Therapeutics (NASDAQ:MLYS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends. Which has more risk and volatility, SVA or MLYS? Sinovac Biotech has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Do analysts recommend SVA or MLYS? Mineralys Therapeutics has a consensus price target of $43.50, suggesting a potential upside of 3.18%. Given Mineralys Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Mineralys Therapeutics is more favorable than Sinovac Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Mineralys Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Which has higher earnings & valuation, SVA or MLYS? Sinovac Biotech has higher revenue and earnings than Mineralys Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSinovac Biotech$448.27M1.44-$99.92MN/AN/AMineralys TherapeuticsN/AN/A-$177.81M-$3.56-11.84 Is SVA or MLYS more profitable? Sinovac Biotech's return on equity of 0.00% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sinovac BiotechN/A N/A N/A Mineralys Therapeutics N/A -70.44%-65.51% Do insiders & institutionals believe in SVA or MLYS? 84.5% of Mineralys Therapeutics shares are held by institutional investors. 12.8% of Sinovac Biotech shares are held by company insiders. Comparatively, 25.6% of Mineralys Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media prefer SVA or MLYS? In the previous week, Mineralys Therapeutics had 4 more articles in the media than Sinovac Biotech. MarketBeat recorded 5 mentions for Mineralys Therapeutics and 1 mentions for Sinovac Biotech. Mineralys Therapeutics' average media sentiment score of 0.42 beat Sinovac Biotech's score of 0.00 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Sinovac Biotech Neutral Mineralys Therapeutics Neutral SummaryMineralys Therapeutics beats Sinovac Biotech on 7 of the 12 factors compared between the two stocks. Get Sinovac Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for SVA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SVA vs. The Competition Export to ExcelMetricSinovac BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$644.67M$3.32B$6.01B$10.23BDividend YieldN/A2.29%5.66%4.69%P/E RatioN/A22.1185.3526.57Price / Sales1.44416.63582.95179.01Price / Cash38.9547.1938.3262.20Price / Book0.0510.2112.726.53Net Income-$99.92M-$52.40M$3.30B$275.87M Sinovac Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SVASinovac BiotechN/A$6.47flatN/AN/A$644.67M$448.27M0.003,261High Trading VolumeMLYSMineralys Therapeutics1.7974 of 5 stars$38.58-2.0%$43.50+12.8%+187.3%$2.56BN/A-10.8328Analyst ForecastTARSTarsus Pharmaceuticals0.6921 of 5 stars$59.05+1.7%$66.67+12.9%+102.6%$2.49B$182.95M-25.3150Positive NewsAnalyst ForecastCDTXCidara Therapeutics4.0802 of 5 stars$97.28+2.1%$119.43+22.8%+941.0%$2.46B$1.27M-8.7190Trending NewsAnalyst ForecastGap UpALVOAlvotech3.1974 of 5 stars$8.14-3.1%$14.00+72.0%-36.1%$2.45B$560.10M35.391,032Analyst ForecastFOLDAmicus Therapeutics4.4987 of 5 stars$7.85-1.2%$15.78+101.1%-18.6%$2.42B$571.16M-65.37480Analyst ForecastAnalyst RevisionBEAMBeam Therapeutics3.1171 of 5 stars$23.57-1.4%$46.40+96.9%+18.9%$2.39B$63.52M-5.24510News CoveragePositive NewsAnalyst ForecastIDYAIDEAYA Biosciences4.0985 of 5 stars$27.21+0.1%$43.36+59.4%-9.1%$2.38B$7M-7.1780Analyst ForecastBLTEBelite Bio2.5277 of 5 stars$73.25+0.3%$96.00+31.1%+42.7%$2.33BN/A-47.2610Positive NewsAnalyst ForecastIRONDisc Medicine2.4087 of 5 stars$65.76+1.1%$98.30+49.5%+51.3%$2.29BN/A-14.7130News CoverageAnalyst ForecastInsider TradeIBRXImmunityBio2.693 of 5 stars$2.42-6.0%$10.75+345.1%-26.5%$2.28B$14.74M-5.03590Positive News Related Companies and Tools Related Companies MLYS Alternatives TARS Alternatives CDTX Alternatives ALVO Alternatives FOLD Alternatives BEAM Alternatives IDYA Alternatives BLTE Alternatives IRON Alternatives IBRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SVA) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersThe best AI stock you aren’t watching (but Elon is)Elon Musk's AI empire is already being built... not in the spotlight, but in the background. One public cou...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredU.S. Government Sparking Crypto RallyAltcoin ETFs could surge prices (do this now) My "Crypto Bull Run Millionaire Blueprint" breaks down exactl...Crypto 101 Media | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredBig Oil Firm Stakes $1 Billion in Startup That Could Kill Big OilOn September 22, the unthinkable happened... One of the world's biggest oil producers poured $1 billion int...Stansberry Research | SponsoredToo busy for AI trading?Last week, Nvidia and AMD stock soared as export restrictions eased. Nvidia alone gained nearly 5% in a sin...Timothy Sykes | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sinovac Biotech, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sinovac Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
